Lerociclib is a Small Molecule owned by G1 Therapeutics, and is involved in 10 clinical trials, of which 2 were completed, 6 are ongoing, and 2 are planned.

lerociclib elicits anti-neoplastic effect. The drug candidate inhibits cyclin-dependent kinase (CDK) 4/6. The drug candidate acts by inhibiting cell-cycle progression from G1 to S phase, resulting in suppression of DNA replication and decreased tumor cell proliferation which results in cells that are more resistant to DNA damage. It inhibits retinoblastoma (Rb) protein phosphorylation in early G1 stage. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth.

The revenue for Lerociclib is expected to reach a total of $181m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lerociclib NPV Report.

Lerociclib is originated and owned by G1 Therapeutics. EQRx is the other company associated in development or marketing of Lerociclib.

Lerociclib Overview

lerociclib is under development for the treatment of estrogen-receptor positive, hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, castrate-resistant prostate cancer and non-small cell lung cancer (NSCLC). The drug candidate is administered through oral route. It acts by targeting cyclin-dependent kinases (CDK) 4 and 6.

EQRx Overview

EQRx is a biotechnology company that focuses on creating novel patent-protected medicines at lower prices. The company leverages advanced science and technology techniques focused on re-engineering the process of drug discovery and development of small molecule and biologic drugs for life threatening and chronic diseases treatments, with significant focus on cancer, immuno-inflammatory and genetic diseases. EQRx offers new medications less than the price of traditional pharmaceutical companies, and markets directly to payers and hospital systems instead of consumers. The company is funded by Google Ventures, ARCH Venture Partners LP, Andreessen Horowitz LLC, Casdin Capital LLC, Section 32, Nextech Venture Ltd and Arboretum Ventures LLC. EQRx is headquartered in Cambridge, Massachusetts, the US.

The operating loss of the company was US$196.4 million in FY2021, compared to an operating loss of US$250.1 million in FY2020. The net loss of the company was US$100 million in FY2021, compared to a net loss of US$250 million in FY2020.

Quick View – Lerociclib

Report Segments
  • Innovator
Drug Name
  • Lerociclib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.